239
Participants
Start Date
February 28, 2018
Primary Completion Date
August 20, 2020
Study Completion Date
August 20, 2020
Eversense XL CGM System
The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
Usual SMBG or FGM device used by participants
Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
APHM - Hopital Sainte-Marguerite, Marseille
CHU Caen Normandie, Caen
Institut de diabétologie et Nutrition du Centre, Vernouillet
Hopital Caremeau-CHU Nimes, Nîmes
CHU de Toulouse, Toulouse
CHU de Montpellier, Montpellier
CHU Grenoble Alpes, La Tronche
CHU de Nantes, Saint-Herblain
CHU Reims, Reims
CHU de Nancy, Vandœuvre-lès-Nancy
CHRU de Lille, Lille
CHRU de Strasbourg, Strasbourg
Groupe hospitalier Les Portes du Sud, Vénissieux
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hopital Hotel Dieu - Creusot, Le Creusot
Paris Lariboisière, Paris
APHP Groupe Hospitalier Cochin (Paris), Paris
CHU Rouen, Rouen
CHU Amiens Picardie, Amiens
CHU de Poitiers, Poitiers
Roche Diabetes Care
INDUSTRY
Hoffmann-La Roche
INDUSTRY